Amyloid formation by globular proteins under native conditions

Nature Chemical Biology

Volumn 5, Issue 1, 2009, Pages 15-22

  Chiti, Fabrizio ^a   Dobson, Christopher M ^b  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLPHOSPHATASE; AMYLOID; BETA MICROGLOBULIN; COPPER ZINC SUPEROXIDE DISMUTASE; GLOBULAR PROTEIN; GLOBULIN; PREALBUMIN; UNCLASSIFIED DRUG;

HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN FOLDING; PROTEIN STRUCTURE; REVIEW; SULFOLOBUS SOLFATARICUS;

EID: 57749098600     PISSN: 15524450     EISSN: 15524469     Source Type: Journal    
DOI: 10.1038/nchembio.131     Document Type: Review

References (77)

1. Selkoe, D.J. Folding proteins in fatal ways. Nature 426, 900-904 (2003).
2. Westermark, P. et al. Amyloid: toward terminology clarification. Report from the Nomenclature Committee of the International Society of Amyloidosis. Amyloid 12, 1-4 (2005).
3. Chiti, F. & Dobson, C.M. Protein misfolding, functional amyloid, and human disease. Annu. Rev. Biochem. 75, 333-366 (2006).
4. Bemporad, F. et al. Sequence and structural determinants of amyloid fibril formation. Acc. Chem. Res. 39, 620-627 (2006).
5. Guijarro, J.I., Sunde, M., Jones, J.A., Campbell, I.D. & Dobson, C.M. Amyloid fibril formation by an SH3 domain. Proc. Natl. Acad. Sci. USA 95, 4224-4228 (1998).
6. McParland, V.J. et al. Partially unfolded states of beta(2)-microglobulin and amyloid formation in vitro. Biochemistry 39, 8735-8746 (2000).
7. Litvinovich, S.V. et al. Formation of amyloid-like fibrils by self-association of a partially unfolded fibronectin type III module. J. Mol. Biol. 280, 245-258 (1998).
8. Fändrich, M., Fletcher, M.A. & Dobson, C.M. Amyloid fibrils from muscle myoglobin. Nature 410, 165-166 (2001).
9. Ferrão-Gonzales, A.D., Souto, S.O., Silva, J.L. & Foguel, D. The preaggregated state of an amyloidogenic protein: hydrostatic pressure converts native transthyretin into the amyloidogenic state. Proc. Natl. Acad. Sci. USA 97, 6445-6450 (2000).
10. De Felice, F.G. et al. Formation of amyloid aggregates from human lysozyme and its disease-associated variants using hydrostatic pressure. FASEB J. 18, 1099-1101 (2004).
11. Chiti, F. et al. Designing conditions for in vitro formation of amyloid protofilaments and fibrils. Proc. Natl. Acad. Sci. USA 96, 3590-3594 (1999).
12. Schmittschmitt, J.P. & Scholtz, J.M. The role of protein stability, solubility, and net charge in amyloid fibril formation. Protein Sci. 12, 2374-2378 (2003).
13. Booth, D.R. et al. Instability, unfolding and aggregation of human lysozyme variants underlying amyloid fibrillogenesis. Nature 385, 787-793 (1997).
14. Raffen, R. et al. Physicochemical consequences of amino acid variations that contribute to fibril formation by immunoglobulin light chains. Protein Sci. 8, 509-517 (1999).
15. Stathopulos, P.B. et al. Cu/Zn superoxide dismutase mutants associated with amyotrophic lateral sclerosis show enhanced formation of aggregates in vitro. Proc. Natl. Acad. Sci. USA 100, 7021-7026 (2003).
16. Sekijima, Y. et al. The biological and chemical basis for tissue-selective amyloid disease. Cell 121, 73-85 (2005).
17. Kelly, J.W. Alternative conformations of amyloidogenic proteins govern their behavior. Curr. Opin. Struct. Biol. 6, 11-17 (1996).
18. Dobson, C.M. Protein misfolding, evolution and disease. Trends Biochem. Sci. 24, 329-332 (1999).
19. Frauenfelder, H., Sligar, S.G. & Wolynes, P.G. The energy landscapes and motions of proteins. Science 254, 1598-1603 (1991).
20. Karplus, M. & McCammon, J.A. Molecular dynamics simulations of biomolecules. Nat. Struct. Biol. 9, 646-652 (2002).
21. nd edn. (ed. Pain, R.) 70-72 (Oxford University Press, Oxford, 2000).
22. Pepys, M.B. et al. Human lysozyme gene mutations cause hereditary systemic amyloidosis. Nature 362, 553-557 (1993).
23. Valleix, S. Hereditary renal amyloidosis caused by a new variant lysozyme W64R in a French family. Kidney Int. 61, 907-912 (2002).
24. Yazaki, M., Farrell, S.A. & Benson, M.D. A novel lysozyme mutation Phe57Ile associated with hereditary renal amyloidosis. Kidney Int. 63, 1652-1657 (2003).
25. Röcken, C. et al. ALys amyloidosis caused by compound heterozygosity in exon 2 (Thr70Asn) and exon 4 (Trp112Arg) of the lysozyme gene. Hum. Mutat. 27, 119-120 (2006).
26. Canet, D. et al. Local cooperativity in the unfolding of an amyloidogenic variant of human lysozyme. Nat. Struct. Biol. 9, 308-315 (2002).
27. Dumoulin, M. et al. Reduced global cooperativity is a common feature underlying the amyloidogenicity of pathogenic lysozyme mutations. J. Mol. Biol. 346, 773-788 (2005).
28. Canet, D. et al. Mechanistic studies of the folding of human lysozyme and the origin of amyloidogenic behavior in its disease-related variants. Biochemistry 38, 6419-6427 (1999).
29. Frare, E. et al. Identification of the core structure of lysozyme amyloid fibrils by proteolysis. J. Mol. Biol. 361, 551-561 (2006).
30. Johnson, R.J. et al. Rationalising lysozyme amyloidosis: insights from the structure and solution dynamics of T70N lysozyme. J. Mol. Biol. 352, 823-836 (2005).
31. Dumoulin, M., Kumita, J.R. & Dobson, C.M. Normal and aberrant biological self-assembly: insights from studies of human lysozyme and its amyloidogenic variants. Acc. Chem. Res. 39, 603-610 (2006).
32. Plakoutsi, G., Taddei, N., Stefani, M. & Chiti, F. Aggregation of the acylphosphatase from Sulfolobus solfataricus: the folded and partially unfolded states can both be precursors for amyloid formation. J. Biol. Chem. 279, 14111-14119 (2004).
33. Plakoutsi, G. et al. Evidence for a mechanism of amyloid formation involving molecular reorganisation within native-like precursor aggregates. J. Mol. Biol. 351, 910-922 (2005).
34. Plakoutsi, G. et al. Exploring the mechanism of formation of native-like and precursor amyloid oligomers for the native acylphosphatase from Sulfolobus solfataricus. Structure 14, 993-1001 (2006).
35. Soldi, G., Bemporad, F. & Chiti, F. The degree of structural protection at the edge β-strands determines the pathway of amyloid formation in globular proteins. J. Am. Chem. Soc. 130, 4295-4302 (2008).
36. Bemporad, F., Vannocci, T., Varela, L., Azuaga, A.I. & Chiti, F. A model for the aggregation of the acylphosphatase from Sulfolobus solfataricus in its native-like state. Biochim. Biophys. Acta 1784, 1986-1996 (2008).
37. Watanabe, M. et al. A novel missense point mutation (S134N) of the Cu/Zn superoxide dismutase gene in a patient with familial motor neuron disease. Hum. Mutat. 9, 69-71 (1997).
38. Elam, J.S. et al. Amyloid-like filaments and water-filled nanotubes formed by SOD1 mutant proteins linked to familial ALS. Nat. Struct. Biol. 10, 461-467 (2003).
39. Banci, L. et al. Fully metallated S134N Cu,Zn-superoxide dismutase displays abnormal mobility and intermolecular contacts in solution. J. Biol. Chem. 280, 35815-35821 (2005).
40. Antonyuk, S. et al. Structural consequences of the familial amyotrophic lateral sclerosis SOD1 mutant His46Arg. Protein Sci. 14, 1201-1213 (2005).
41. Cao, X. et al. Structures of the G85R variant of SOD1 in familial amyotrophic lateral sclerosis. J. Biol. Chem. 283, 16169-16177 (2008).
42. Wang, Q., Johnson, J.L., Agar, N.Y. & Agar, J.N. Protein aggregation and protein instability govern familial amyotrophic lateral sclerosis patient survival. PLoS Biol. 6, e170 (2008).
43. Nordlund, A. & Oliveberg, M. Folding of Cu/Zn superoxide dismutase suggests structural hotspots for gain of neurotoxic function in ALS: parallels to precursors in amyloid disease. Proc. Natl. Acad. Sci. USA 103, 10218-10223 (2006).
44. Benson, M.D. & Kincaid, J.S. The molecular biology and clinical features of amyloid neuropathy. Muscle Nerve 36, 411-423 (2007).
45. Blake, C.C., Burridge, J.M. & Oatley, S.J. X-ray analysis of thyroid hormone binding to prealbumin. Biochem. Soc. Trans. 6, 1114-1118 (1978).
46. Colon, W. & Kelly, J.W. Partial denaturation of transthyretin is sufficient for amyloid fibril formation in vitro. Biochemistry 31, 8654-8660 (1992).
47. Lai, Z., Colón, W. & Kelly, J.W. The acid-mediated denaturation pathway of transthyretin yields a conformational intermediate that can self-assemble into amyloid. Biochemistry 35, 6470-6482 (1996).
48. Quintas, A., Vaz, D.C., Cardoso, I., Saraiva, M.J. & Brito, R.M. Tetramer dissociation and monomer partial unfolding precedes protofibril formation in amyloidogenic transthyretin variants. J. Biol. Chem. 276, 27207-27213 (2001).
49. Liu, K. et al. Deuterium-proton exchange on the native wild-type transthyretin tetramer identifies the stable core of the individual subunits and indicates mobility at the subunit interface. J. Mol. Biol. 303, 555-565 (2000).
50. Liu, K., Cho, H.S., Lashuel, H.A., Kelly, J.W. & Wemmer, D.E. A glimpse of a possible amyloidogenic intermediate of transthyretin. Nat. Struct. Biol. 7, 754-757 (2000).
51. Hörnberg, A., Olofsson, A., Eneqvist, T., Lundgren, E. & Sauer-Eriksson, A.E. The β-strand D of transthyretin trapped in two discrete conformations. Biochim. Biophys. Acta 1700, 93-104 (2004).
52. Serag, A.A., Altenbach, C., Gingery, M., Hubbell, W.L. & Yeates, T.O. Identification of a subunit interface in transthyretin amyloid fibrils: evidence for self-assembly from oligomeric building blocks. Biochemistry 40, 9089-9096 (2001).
53. Serag, A.A., Altenbach, C., Gingery, M., Hubbell, W.L. & Yeates, T.O. Arrangement of subunits and ordering of β-strands in an amyloid sheet. Nat. Struct. Biol. 9, 734-739 (2002).
54. Olofsson, A., Ippel, J.H., Wijmenga, S.S., Lundgren, E. & Ohman, A. Probing solvent accessibility of transthyretin amyloid by solution NMR spectroscopy. J. Biol. Chem. 279, 5699-5707 (2004).
55. Gejyo, F. et al. A new form of amyloid protein associated with chronic hemodialysis was identified as β2-microglobulin. Biochem. Biophys. Res. Commun. 129, 701-706 (1985).
56. Esposito, G. et al. Removal of the N-terminal hexapeptide from human β2-microglobulin facilitates protein aggregation and fibril formation. Protein Sci. 9, 831-845 (2000).
57. Chiti, F. et al. Detection of two partially structured species in the folding process of the amyloidogenic protein β 2-microglobulin. J. Mol. Biol. 307, 379-391 (2001).
58. Kameda, A. et al. Nuclear magnetic resonance characterization of the refolding intermediate of β2-microglobulin trapped by non-native prolyl peptide bond. J. Mol. Biol. 348, 383-397 (2005).
59. Jahn, T.R., Parker, M.J., Homans, S.W. & Radford, S.E. Amyloid formation under physiological conditions proceeds via a native-like folding intermediate. Nat. Struct. Mol. Biol. 13, 195-201 (2006).
60. Chiti, F. et al. A partially structured species of β 2-microglobulin is significantly populated under physiological conditions and involved in fibrillogenesis. J. Biol. Chem. 276, 46714-46721 (2001).
61. Eakin, C.M., Attenello, F.J., Morgan, C.J. & Miranker, A.D. Oligomeric assembly of native-like precursors precedes amyloid formation by β-2 microglobulin. Biochemistry 43, 7808-7815 (2004).
62. Eakin, C.M., Berman, A.J. & Miranker, A.D. A native to amyloidogenic transition regulated by a backbone trigger. Nat. Struct. Mol. Biol. 13, 202-208 (2006).
63. Verdone, G. et al. The solution structure of human β2-microglobulin reveals the prodromes of its amyloid transition. Protein Sci. 11, 487-499 (2002).
64. Eakin, C.M., Knight, J.D., Morgan, C.J., Gelfand, M.A. & Miranker, A.D. Formation of a copper specific binding site in non-native states of β-2-microglobulin. Biochemistry 41, 10646-10656 (2002).
65. Calabrese, M.F. & Miranker, A.D. Formation of a stable oligomer of β-2 microglobulin requires only transient encounter with Cu(II). J. Mol. Biol. 367, 1-7 (2007).
66. Calabrese, M.F., Eakin, C.M., Wang, J.M. & Miranker, A.D. A regulatable switch mediates self-association in an immunoglobulin fold. Nat. Struct. Mol. Biol. advance online publication, doi:10.1038/nsmb.1483 (August 2008).
67. Kameda, A. et al. Nuclear magnetic resonance characterization of the refolding intermediate of β2-microglobulin trapped by non-native prolyl peptide bond. J. Mol. Biol. 348, 383-397 (2005).
68. Esposito, G. et al. The controlling roles of Trp60 and Trp95 in β2-microglobulin function, folding and amyloid aggregation properties. J. Mol. Biol. 378, 887-897.
69. Johnson, S.M. et al. Native state kinetic stabilization as a strategy to ameliorate protein misfolding diseases: a focus on the transthyretin amyloidoses. Acc. Chem. Res. 38, 911-921 (2005).
70. Ray, S.S., Nowak, R.J., Brown, R.H. Jr. & Lansbury, P.T. Jr. Small-molecule-mediated stabilization of familial amyotrophic lateral sclerosis-linked superoxide dismutase mutants against unfolding and aggregation. Proc. Natl. Acad. Sci. USA 102, 3639-3644 (2005).
71. Soldi, G., Plakoutsi, G., Taddei, N. & Chiti, F. Stabilization of a native protein mediated by ligand binding inhibits amyloid formation independently of the aggregation pathway. J. Med. Chem. 49, 6057-6064 (2006).
72. Dumoulin, M. et al. A camelid antibody fragment inhibits the formation of amyloid fibrils by human lysozyme. Nature 424, 783-788 (2003).
73. Bouchard, M., Zurdo, J., Nettleton, E.J., Dobson, C.M. & Robinson, C.V. Formation of insulin amyloid fibrils followed by FTIR simultaneously with CD and electron microscopy. Protein Sci. 9, 1960-1967 (2000).
74. Pedersen, J.S., Christensen, G. & Otzen, D.E. Modulation of S6 fibrillation by unfolding rates and gatekeeper residues. J. Mol. Biol. 341, 575-588 (2004).
75. Chow, M.K., Ellisdon, A.M., Cabrita, L.D. & Bottomley, S.P. Polyglutamine expansion in ataxin-3 does not affect protein stability: implications for misfolding and disease. J. Biol. Chem. 279, 47643-47651 (2004).
76. Soldi, G. et al. Amyloid formation of a protein in the absence of initial unfolding and destabilization of the native state. Biophys. J. 89, 4234-4244 (2005).
77. Iannuzzi, C., Vilasi, S., Portaccio, M., Irace, G. & Sirangelo, I. Heme binding inhibits the fibrillization of amyloidogenic apomyoglobin and determines lack of aggregate cytotoxicity. Protein Sci. 16, 507-516 (2007).